Tag Archive for: financing

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

/in

HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative […]

Read more

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

/in

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need Boston, Massachusetts and Geneva, Switzerland, 12th February 2024 – Alys Pharmaceuticals, Inc. […]

Read more

DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform

/in

New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery technology platform towards the clinic and further build DelSiTech Turku, Finland – 16th January 2024. Clinical-stage drug delivery and development company DelSiTech, today announces the successful completion of a EUR 10 million financing round, the […]

Read more

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

/in

Tenmile and Novo Holdings are core investors Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms SAN FRANCISCO, Jan. 5, 2024 – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced […]

Read more

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

/in

New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company’s efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a […]

Read more